文献速递胸部肿瘤

STK11和KEAP1突变肺腺癌中程序性死亡-(配体)1抑制疗效降低受KRAS突变状态影响

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
PubMed 文献 · J Thorac Oncol · 2021-11-02

研究纳入两个独立队列共1261例晚期肺腺癌患者,分析KRAS、STK11和KEAP1突变状态与PD-(L)1抑制疗效的关系。结果显示,仅在KRAS突变肺腺癌中,STK11和KEAP1突变与免疫治疗的无进展生存和总生存显著更差相关,而在KRAS野生型中无此关联。

要点

  • 在KRAS突变肺腺癌中,STK11突变与免疫治疗无进展生存(HR=2.04,p<0.0001)和总生存(HR=2.09,p<0.0001)显著更差相关。
  • 在KRAS突变肺腺癌中,KEAP1突变与免疫治疗无进展生存(HR=2.05,p<0.0001)和总生存(HR=2.24,p<0.0001)显著更差相关。
  • 在KRAS野生型肺腺癌中,STK11和KEAP1突变与免疫治疗疗效无显著关联。

核心结论

  • STK11和KEAP1突变在KRAS突变肺腺癌患者中导致免疫治疗结局更差,但在KRAS野生型肺腺癌中未观察到此效应。
  • 同时携带KRAS/STK11和KRAS/KEAP1突变的肿瘤在基因表达和免疫细胞浸润方面显示不同的免疫特征。

研究设计与样本

  • 研究收集2013年9月至2020年9月期间Dana-Farber癌症研究所/麻省总医院队列和Memorial Sloan Kettering癌症中心/MD Anderson癌症中心队列的晚期肺腺癌患者的临床病理和基因组数据。
  • 在两个独立队列中根据KRAS、STK11和KEAP1突变状态分析PD-(L)1抑制的临床结局。
  • 利用癌症基因组图谱转录组数据,分别根据KRAS/STK11和KRAS/KEAP1共突变状态识别肿瘤基因表达和肿瘤免疫细胞亚群的差异。

主要发现

  • 合并队列共1261例患者(中位年龄=61岁[范围:22-92],女性708例[56.1%],吸烟者1065例[84.4%]),KRAS突变536例(42.5%),可评估病例中STK11和KEAP1有害突变分别占20.6%(260/1261)和19.2%(231/1202)。
  • 在每个独立队列和合并队列中,STK11和KEAP1突变与免疫治疗的无进展生存(STK11 HR=2.04,p<0.0001;KEAP1 HR=2.05,p<0.0001)和总生存(STK11 HR=2.09,p<0.0001;KEAP1 HR=2.24,p<0.0001)显著更差相关,且仅在KRAS突变肺腺癌中,而非KRAS野生型肺腺癌中。
  • 基因表达本体和免疫细胞富集分析显示,STK11或KEAP1突变的存在导致KRAS突变肺癌中不同的免疫表型,但在KRAS野生型肺癌中未导致。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: STK11 and KEAP1 mutations (STK11 mutant [STK11MUT] and KEAP1MUT) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11MUT has been associated with resistance to programmed death-(ligand)1 (PD-[L]1) inhibition in KRASMUT LUAD, its impact on immunotherapy efficacy in KRAS wild-type (KRASWT) LUAD is currently unknown. Whether KEAP1MUT differentially affects outcomes to PD-(L)1 inhibition in KRASMUT and KRASWT LUAD is also unknown. METHODS: Clinicopathologic and genomic data were collected from September 2013 to September 2020 from patients with advanced LUAD at the Dana-Farber Cancer Institute/Massachusetts General Hospital cohort and the Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center cohort. Clinical outcomes to PD-(L)1 inhibition were analyzed according to KRAS, STK11, and KEAP1 mutation status in two independent cohorts. The Cancer Genome Atlas transcriptomic data were interrogated to identify differences in tumor gene expression and tumor immune cell subsets, respectively, according to KRAS/STK11 and KRAS/KEAP1 comutation status. RESULTS: In the combined cohort (Dana-Farber Cancer Institute/Massachusetts General Hospital + Memorial Sloan Kettering Cancer Center/MD Anderson Cancer Center) of 1261 patients (median age = 61 y [range: 22-92], 708 women [56.1%], 1065 smokers [84.4%]), KRAS mutations were detected in 536 cases (42.5%), and deleterious STK11 and KEAP1 mutations were found in 20.6% (260 of 1261) and 19.2% (231 of 1202) of assessable cases, respectively. In each independent cohort and in the combined cohort, STK11 and KEAP1 mutations were associated with significantly worse progression-free (STK11 hazard ratio [HR] = 2.04, p < 0.0001; KEAP1 HR = 2.05, p < 0.0001) and overall (STK11 HR = 2.09, p < 0.0001; KEAP1 HR = 2.24, p < 0.0001) survival to immunotherapy uniquely among KRASMUT but not KRASWT LUADs. Gene expression ontology and immune cell enrichment analyses revealed that the presence of STK11 or KEAP1 mutations results in distinct immunophenotypes in KRASMUT, but not in KRASWT, lung cancers. CONCLUSIONS: STK11 and KEAP1 mutations confer worse outcomes to immunotherapy among patients with KRASMUT but not among KRASWT LUAD. Tumors harboring concurrent KRAS/STK11 and KRAS/KEAP1 mutations display distinct immune profiles in terms of gene expression and immune cell infiltration.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ricciuti B, Arbour KC, Lin JJ, et al. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol. 2021. PMID: 34740862. doi:10.1016/j.jtho.2021.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。